Retatrutide's Phase 2 obesity trial pushed the dose up to 12 mg once weekly and produced mean weight loss of roughly 24% at 48 weeks — the largest percentage ever reported in a published weight-loss drug trial at that point. The dose that gets you there is not something you jump straight to; it's a slow titration over roughly 20 weeks. Here is how the schedule actually looked, and how the Phase 3 TRIUMPH-1 program is doing it.
Key Takeaways
- Retatrutide is once-weekly subcutaneous. Same cadence as semaglutide and tirzepatide.
- Phase 2 tested four target doses. 1, 4, 8 (two schedules), and 12 mg once weekly, with slow titration to each target.
- TRIUMPH-1 titrates every 4 weeks. Starts at 0.5 mg, moves through 1.5 mg and 3 mg, then steps up to 6 mg or 12 mg maintenance.
- Dose-response is steep. Mean weight loss climbs from ~8% at 1 mg to ~24% at 12 mg over 48 weeks.
- Slower titration improves tolerability. This mirrors what semaglutide and tirzepatide experience showed.
- Maintenance length is still being characterized. Phase 3 extends on-treatment follow-up to 72 weeks.
How retatrutide is administered
Retatrutide is a once-weekly subcutaneous injection. In both Phase 2 and Phase 3, dosing is same day of week, independent of meals, injected into the abdomen, thigh, or upper arm — the familiar GLP-1 class playbook. Dose escalation is scheduled rather than symptom-driven, so a titration map tells you what to expect week by week.
The Phase 2 dose arms (NEJM 2023)
The Jastreboff Phase 2 trial randomized 338 adults with obesity (BMI ≥30, or ≥27 with weight-related comorbidity) to five groups: placebo, 1 mg, 4 mg, 8 mg via two different escalation speeds, and 12 mg. Participants titrated upward over roughly 20 weeks until they reached their assigned maintenance dose, then stayed there through week 48. The two 8 mg arms used different escalation speeds — one faster, one slower — to begin characterizing how much the ramp speed matters for tolerability.
TRIUMPH-1 Phase 3 titration schedule
TRIUMPH-1 locked in a cleaner titration pattern. Participants start at 0.5 mg and step up every 4 weeks to a maintenance dose of 6 mg or 12 mg. The target dose is reached by about week 20 for the 12 mg arm and by about week 16 for the 6 mg arm.
| Weeks | Dose for 6 mg arm | Dose for 12 mg arm |
|---|---|---|
| Weeks 1–4 | 0.5 mg | 0.5 mg |
| Weeks 5–8 | 1.5 mg | 1.5 mg |
| Weeks 9–12 | 3 mg | 3 mg |
| Weeks 13–16 | 4.5 mg | 6 mg |
| Weeks 17–20 | 6 mg (maintenance) | 9 mg |
| Weeks 21+ | 6 mg (maintenance) | 12 mg (maintenance) |
The notable feature of this schedule is that every step is a 4-week dwell, long enough for GI side effects from the previous step to settle before pushing further. In Phase 2, the arm that escalated faster to 8 mg reported slightly worse tolerability than the slower arm, which is the empirical basis for the "4 weeks per step" rhythm Phase 3 uses.
Dose-response from Phase 2
The 48-week Phase 2 weight-loss results are what put retatrutide on the map. Mean percent change in body weight scaled with dose, as did the proportion of participants hitting the "really meaningful" thresholds of ≥15%, ≥20%, and ≥25% total weight loss.
| Dose arm | Mean weight loss at 48 wk | ≥15% loss | ≥20% loss | ≥25% loss |
|---|---|---|---|---|
| Placebo | ~2% | ~2% | ~0% | ~0% |
| 1 mg | ~8% | ~22% | ~5% | ~0% |
| 4 mg | ~17% | ~60% | ~27% | ~9% |
| 8 mg | ~22% | ~75% | ~55% | ~27% |
| 12 mg | ~24% | ~83% | ~63% | ~48% |
Values above are approximate from the published figures and tables and should be read as magnitudes rather than exact percentages. Three things stand out. First, even the 1 mg arm beat placebo by roughly 6 percentage points. Second, moving from 4 mg to 8 mg roughly doubled the proportion hitting ≥20%. Third, almost half of the 12 mg arm hit ≥25% weight loss in 48 weeks — a threshold that semaglutide and tirzepatide rarely reach at that time point.
Maintenance length and how long people stay at target
In Phase 2, maintenance ran from week ~20 through week 48 — roughly 28 weeks at target dose. In Phase 3 TRIUMPH-1, follow-up is extended to 72 weeks, which means maintenance stretches to roughly 52 weeks at target. That extra year of exposure is central to understanding both durability of weight loss and whether tolerability stays stable at the top dose.
Dosing differences by indication
Retatrutide is being developed across multiple indications — obesity (TRIUMPH-1, -3, -5), type 2 diabetes (TRIUMPH-4), and others. Dosing between indications may differ. In the type 2 diabetes arm, the trade-off between glucose control and tolerability may land on a lower maintenance dose than for pure weight management. The 6 mg maintenance arm in TRIUMPH-1 is partly a hedge — some patients may prefer the smaller GI burden of 6 mg at the cost of slightly less weight loss.
Historically, incretin drugs have carried different approved dose ceilings between T2D and obesity indications. Semaglutide tops out at 2.0 mg in Ozempic (T2D) and 2.4 mg in Wegovy (obesity). Tirzepatide goes to 15 mg in both Mounjaro (T2D) and Zepbound (obesity), but the step-wise titration path is similar across indications. Whether retatrutide follows the semaglutide pattern (different top doses by indication) or the tirzepatide pattern (same top dose, same titration) is still to be determined by the regulatory submission.
How the dose-response compares across the incretin class
One way to read the Phase 2 dose-response data is to anchor it against what semaglutide and tirzepatide achieved in their own Phase 3 obesity programs. Semaglutide 2.4 mg produced ~14.9% weight loss over 68 weeks in STEP-1. Tirzepatide 15 mg produced ~20.9% over 72 weeks in SURMOUNT-1. Retatrutide 12 mg produced ~24.0% over just 48 weeks in Phase 2 — a shorter trial and arguably a steeper slope. Whether that extra efficacy is purely a function of adding a third receptor target (glucagon), or partly a function of the specific pharmacokinetic profile Lilly built into retatrutide, is a mechanistic question the Phase 3 program will not entirely answer either. What Phase 3 does need to answer is whether the Phase 2 result is replicable at larger scale with the TRIUMPH-1 slower-titration protocol.
Practical dose-selection framing
For readers trying to understand why TRIUMPH-1 was designed with two maintenance arms (6 mg and 12 mg), the practical logic is straightforward. Not every patient needs or wants the maximum-efficacy dose; some patients will achieve their weight-loss target at 6 mg, with less GI burden and lower injection cost. The 12 mg arm defines the upper end of what the molecule can do. The 6 mg arm defines a lower-friction maintenance option. The final approved label is likely to acknowledge both.
Why 4-week steps
The TRIUMPH-1 titration pattern dwells on each dose for 4 weeks before stepping up. That cadence is not arbitrary. GLP-1 class receptor adaptation — the physiological settling that reduces nausea and vomiting over the first weeks of exposure — appears to track roughly on a 3–4 week timeline. Phase 2 experience with semaglutide and tirzepatide landed on similar 4-week dwell times for exactly the same reason. Shorter steps raise GI event rates during escalation; longer steps delay reaching the efficacy dose. The 4-week step is a compromise that trials have converged on empirically.
In Phase 2, the two 8 mg arms were a controlled experiment on this question. The faster-escalation 8 mg arm hit maintenance earlier but reported slightly worse GI tolerability during the ramp. The slower-escalation 8 mg arm trailed by a few weeks but had cleaner tolerability. The published safety data support the slower ramp.
Missed-dose handling in trial protocols
Trial protocols include guidance for what happens when a participant misses a scheduled weekly dose. The general pattern used in TRIUMPH-1, which echoes semaglutide and tirzepatide protocol language, is: if a dose is missed and the next scheduled dose is more than ~2 days away, take the missed dose; if the next scheduled dose is within ~2 days, skip the missed dose and resume the normal schedule. Multiple consecutive missed doses may trigger a step back down to a lower titration dose at the next administration. These are protocol conventions, not blanket clinical instructions, and specific label language will differ when the drug issues.
What this does not tell you
A titration schedule is only part of the clinical picture. It does not tell you who should be on the drug at all, what maintenance dose a given person should sit at, how to handle a missed dose, or how to taper if someone is coming off. It also does not tell you anything about dosing in populations the trials excluded — pregnancy, pediatric, severe hepatic impairment. The actual approved label, when it issues, will carry specific guidance on all of these points that trial protocols do not.
Conclusion
Retatrutide's dosing architecture is familiar: once-weekly subcutaneous, 4-week titration steps, a maintenance dose chosen between a lower-tolerability option and a maximum-efficacy option. The published Phase 2 data show a steep dose-response up to 12 mg, and TRIUMPH-1 is testing whether the slow, patient titration schedule holds that efficacy with better tolerability than the fastest Phase 2 arms.
Any practical use of this information outside a clinical trial should be driven by the FDA label when it eventually publishes and by a prescriber. Until then, treat the schedules above as research-trial doses, not off-the-shelf protocols.
Frequently Asked Questions
What dose of retatrutide was used in the NEJM Phase 2 trial?
The trial tested 1, 4, 8 (two different escalation schedules), and 12 mg once weekly, titrated upward over roughly 20 weeks before reaching maintenance.
How long does it take to reach the maintenance dose?
In TRIUMPH-1, participants reach 6 mg maintenance by about week 17 and 12 mg maintenance by about week 21, with 4-week steps between each dose.
What is the starting dose of retatrutide?
TRIUMPH-1 starts at 0.5 mg once weekly for the first 4 weeks before stepping to 1.5 mg.
Is retatrutide once a week?
Yes. Retatrutide is dosed once weekly by subcutaneous injection, independent of meals.
How much weight did people lose on retatrutide 12 mg?
In Phase 2 at 48 weeks, mean weight loss on the 12 mg arm was roughly 24%, with almost half of participants losing ≥25% of baseline body weight.
Can the dose be lowered if side effects are bad?
In trial protocols, participants who did not tolerate a step could stay longer at the previous dose or step down. This is a trial-defined option, not a general prescribing instruction.
Primary sources:
- Jastreboff AM et al. Retatrutide for Obesity — Phase 2. NEJM 2023.
- NEJM full-text: Retatrutide Phase 2 obesity trial
- ClinicalTrials.gov: TRIUMPH-1 Phase 3 titration protocol
- Eli Lilly investor press releases
- PubMed: Retatrutide publication index
Research disclaimer: Retatrutide is not FDA-approved at the time of writing. Dosing schedules described here are from clinical trial protocols and the published NEJM Phase 2 paper. This article is a research summary for educational use only and is not medical advice. Do not use trial protocols as prescriptions.
